logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
ESLA
Estrella Immunopharma, Inc.
0.72
1 x 0.72
1 x 0.75
bid
ask
-
0.00
0.14%
09:30 AM
timesize
Ytd-53.78%
1y-12.39%
0.72
day range
0.72
0.68
52 week range
3.15
Open0.72Prev Close0.72Low0.72High0.72Mkt Cap30.76M
Vol160.00Avg Vol39.61KEPS-0.35P/E-2.08Forward P/EN/A
Beta0.88Short Ratio0.07Inst. Own0.55%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg0.91200-d Avg1.361yr Est0.00

ESLA News

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Sit

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
businesswire.com
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/S

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
businesswire.com
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tand

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #2026TandemMeetings--Estrella Immunopharma, Inc. (Nasdaq: ESLA

Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
businesswire.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB10

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
businesswire.com
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Pr

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
businesswire.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a c

Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
defenseworld.net
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast

Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
businesswire.com
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
businesswire.com
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Respo

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
businesswire.com
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas
businesswire.com
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
businesswire.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Init

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” o

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target o

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
businesswire.com
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTE

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” o
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket

Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a propos
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 369 companies hit new 52-week lows.